GLMD
Galmed Pharmaceuticals Ltd
NASDAQ: GLMD · HEALTHCARE · BIOTECHNOLOGY
$0.56
-4.92% today
Updated 2026-04-29
Market cap
$4.12M
P/E ratio
—
P/S ratio
61.38x
EPS (TTM)
$-2.39
Dividend yield
—
52W range
$0 – $2
Volume
3.7M
Galmed Pharmaceuticals Ltd (GLMD) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-64.20%
ROA
-28.60%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | — | $-3.15M | — | — | — |
| 2013 | $0.00 | $-17.48M | — | — | — |
| 2014 | $0.00 | $-9.10M | — | — | — |
| 2015 | $0.00 | $-10.62M | — | — | — |
| 2016 | $467000.00 | $-16.95M | 100.00% | -3,614.99% | -3,630.19% |
| 2017 | $1.08M | $-12.30M | 100.00% | -1,139.54% | -1,133.55% |
| 2018 | $2.04M | $-9.86M | 100.00% | -525.76% | -483.61% |
| 2019 | $0.00 | $-20.46M | — | — | — |
| 2020 | $0.00 | $-28.77M | — | — | — |
| 2021 | $0.00 | $-32.47M | — | — | — |
| 2022 | $0.00 | $-17.87M | — | — | — |
| 2023 | $0.00 | $-6.91M | — | — | — |
| 2024 | $0.00 | $-7.52M | — | — | — |
| 2025 | $0.00 | $-10.31M | — | — | — |